Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 215,261,264 papers from all fields of science
Search
Sign In
Create Free Account
Antibody-Drug Conjugate SC16LD6.5
Known as:
Anti-SC16 ADC SC16LD6.5
, SC16LD6.5
An antibody-drug conjugate (ADC) containing an antibody directed against the scr-like kinase Fyn3 (SC-16), conjugated to the cytotoxic agent D6.5…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
L. Puca
,
Katie Gavyert
,
+21 authors
H. Beltran
Science Translational Medicine
2019
Corpus ID: 84841636
DLL3 is overexpressed in neuroendocrine prostate cancer and is a potential therapeutic target. Lessons from one tumor help with…
Expand
Review
2019
Review
2019
Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges
A. Leonetti
,
F. Facchinetti
,
+4 authors
M. Tiseo
Cellular Oncology
2019
Corpus ID: 106411322
Small-cell lung cancer (SCLC) is an aggressive disease with still limited therapeutic options. Despite being both a chemo- and…
Expand
Highly Cited
2017
Highly Cited
2017
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
Sai Kiran Sharma
,
J. Pourat
,
+18 authors
Jason S. Lewis
Cancer Research
2017
Corpus ID: 4772820
The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade…
Expand
2017
2017
Abstract 3093: Expression of DLL3 in metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas as potential indications for rovalpituzumab tesirine (Rova-T; SC16LD6.5…
L. Saunders
,
Samuel A. Williams
,
+27 authors
S. Dylla
2017
Corpus ID: 80600595
Expression of DLL3 was examined in additional tumor types, as it was found to be highly expressed in tumor-initiating cells (TIC…
Expand
2016
2016
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).
C. Rudin
,
M. Pietanza
,
+13 authors
S. Peng
2016
Corpus ID: 78927500
LBA8505Background: SCLC remains among the most deadly of malignancies. Rovalpituzumab tesirine is a first-in-class ADC comprised…
Expand
2016
2016
Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse
S. Dylla
Molecular & Cellular Oncology
2016
Corpus ID: 41908753
ABSTRACT Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug…
Expand
Highly Cited
2015
Highly Cited
2015
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
L. Saunders
,
A. Bankovich
,
+32 authors
S. Dylla
Science Translational Medicine
2015
Corpus ID: 10238367
Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers…
Expand
2003
2003
Formation and relaxation of coherency strain in the nickel-base superalloy SC16.
H. Pinto
,
G. Bruno
Journal of Synchrotron Radiation
2003
Corpus ID: 22089673
An in situ study of the kinetics of relaxation of the gamma-gamma' lattice mismatch in the single-crystal Ni-base superalloy SC16…
Expand
2003
2003
Simulation of solidification and heat treatment of nickel-base superalloy SC16
L. Theoretische
2003
Corpus ID: 138740042
Thermodynamic equilibrium and Gulliver – Scheil as well as diffusion calculations using the DICTRA program have been made to…
Expand
Highly Cited
1995
Highly Cited
1995
First-principles pseudopotential study of the phase stability of the III-V semiconductors GaAs and AlAs.
Mujica
,
Needs
,
Muñoz
Physical Review B (Condensed Matter)
1995
Corpus ID: 8239389
A first-principles pseudopotential study of the phase stability of the III-V semiconductors GaAs and AlAs is reported. For both…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE